.
The deal, disclosed on March 30, pairs the proprietary bfLEAP analytical platform with a top-5 global pharmaceutical company (by 2025 revenue) to identify and prioritize novel drug targets for major depressive disorder. It accelerates the partner's discovery and clinical development program while granting exclusive access to a prioritized target candidate. CEO Vin Singh described it as high-quality validation of the technology's ability to resolve multimodal biological complexity at scale. With the MDD market already over $8 billion and growing nearly 5% annually, the news sparked more than 100% gains the prior day; premarket activity on March 31 reflects sustained follow-through buying, high volume, and retail momentum extending that move. Details appear in the company's Form 8-K.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.